Myelodysplasias:

Myelodysplastic Syndrome (MDS): How common is it? i.e. epidemiology and risk factors.- Therapy related myelodysplasia. Predisposing factors and molecular genetics.- Cytogenetic abnormalities in primary and secondary MDS.- The value of SNP and expression profiling in diagnosis and prognosis.- Molecular pathology of 5q-syndrome and 5q- abnormality.- Genomic instability syndromes and myelodysplasia.- Animal models of myelodysplasia.- Biological defects of haemopoiesis of low risk MDS.- Prognostic evaulation of primary MDS.- FAB, WHO, IWG and beyond.- Methylation and histone acetylation in the context of MDS.- Treatment of MDS with demethylating agents and HDAC inhibitor.- Supportive treatment in low and high risk MDS.- Allogeneic stem cell transplantation in MDS.- Immune dysregulation and immunosuppressive therapy MDS.- Aplastic anaemia/MDS overlap syndrome.- Clinical and molecular spectrum of Myeloproliferative/Myelodysplastic disorders (MPD/MDS).- MPD/MDS overlap syndromes.- Adult and juvenile Chronic Myelomonocytic Leukemia (CMML.- Emerging therapies including Lenolidamide